Clinical Impact of New Data From HIVR4P 2021 Virtual

January 27-28 and February 3-4, 2021
In this downloadable slideset, CCO’s expert faculty members summarize key studies from this important conference, including clinical data on new PrEP options, implementation strategies, multipurpose prevention technologies, and an emerging treatment.
Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD
Kenneth Mayer, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 518 KB
Released: February 17, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Clinical Care Options (CCO) expert commentary by Dr Babafemi Taiwo on how the latest data from the AMBITION-cm trial will affect the treatment of patients with HIV in Africa

Babafemi Taiwo, MBBS Released: September 17, 2021

Dr Milena Murray and Clinical Care Options (CCO): Current pharmacokinetic and safety data support the use of tenofovir alafenamide during pregnancy

person default Milena Murray, PharmD, MSc, BCIDP, AAHIVP Released: September 15, 2021

Download CCO slides reviewing clinically relevant new data reported at IAS 2021 on a wide range of ART management topics.

Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
Daniel R. Kuritzkes, MD
Released: September 13, 2021

Dr Jason Halperin and Clinical Care Options (CCO): Rapid ART in adolescents leads to virologic suppression and upholds equity

Jason Halperin, MD, MPH Released: September 10, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue